# LENSAR

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lensar

- Industry: Medical Devices & Equipment
- Headquarters: Orlando, US
- Website: www.lensar.com
- Total disclosed funding: $45M
- Latest round: Series E (Jan 14, 2015)
- Investors on record: 4

## About

LENSAR, LLC specializes in robotic cataract laser technology, enhancing surgical precision for refractive cataract surgeries. The company focuses on innovative solutions to improve patient outcomes and operational efficiency for ophthalmologists.Founded in 2004 and headquartered in Orlando, US, LENSAR, LLC operates in the ophthalmic surgical market, providing advanced laser technology for cataract surgeries. The company has engaged in a total of 11 deals, with the most recent occurring on March 24, 2025, when Alcon Labs, Inc. acquired LENSAR for approximately USD 365 mn. The CEO, Nick Curtis, leads the company, which has not been reported as a subsidiary of any parent organization or involved in significant pivots or restructures.LENSAR, LLC is at the forefront of robotic cataract laser technology, specifically for refractive cataract surgery. Its flagship product, the LENSAR Robotic Cataract Laser System, offers a comprehensive platform designed to enhance surgical precision and improve clinical outcomes. This system utilizes advanced technologies, including augmented reality and intelligent incisions, to optimize surgical workflows, addressing challenges such as minimizing phacoemulsification energy and improving visual recovery times. LENSAR serves ophthalmologists and surgical centers across North America, Europe, and select regions in Asia.LENSAR generates revenue primarily through the sale of its LENSAR Robotic Cataract Laser System and associated training and support services. The company conducts direct transactions with surgical centers and ophthalmologists, ensuring operational efficiency and customer satisfaction. Revenue streams include the upfront purchase of laser systems and recurring revenues from service agreements and consumable products used in procedures, reflecting the value of enhanced surgical outcomes.Following the acquisition by Alcon Labs, Inc. on March 24, 2025, for approximately USD 356 mn, LENSAR, LLC is positioned to expand its market presence significantly. The acquisition aims to integrate LENSAR’s advanced laser technology into Alcon’s cataract equipment portfolio, enhancing surgery efficiency globally. Future growth strategies may include the launch of upcoming products that leverage this advanced technology and expansion into new markets, particularly targeting regions where cataract surgery demand is increasing. Alcon's commitment to integrating LENSAR's capabilities is expected to facilitate these strategic initiatives.

## Funding rounds

- Series E, Jan 14, 2015, $6M — Aisling Capital
- Series E, Nov 12, 2014, $2M — Aisling Capital
- Series E, Oct 2, 2013, $10M — Hamilton Lane, Aisling Capital, Florida Opportunity Fund
- Series E, Aug 21, 2013, $17M — Aisling Capital, The Florida Growth Fund, Florida Opportunity Fund
- Series E, Dec 17, 2012, $5M — Hamilton Lane
- Series D, Oct 12, 2011, $4M — Aisling Capital

## Investors

- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series D, Series E
- Hamilton Lane (https://capitalatlas.ai/funds/hamilton-lane) — Series E
- The Florida Growth Fund — Series E
- Florida Opportunity Fund (https://capitalatlas.ai/funds/florida-opportunity-fund) — Series E